循环SWAT用于基于深度学习的阿尔茨海默病的诊断分类:对代谢组数据的应用
Taeho Jo1, Junpyo Kim2, Paula Bice1
1Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, 46202, USA; Indiana Alzheimer Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
EBioMedicine
|October 8, 2023
概括
一种新方法,循环滑动窗关联测试 (c-SWAT),改善了阿尔茨海默氏症.
科学领域:
- 计算生物学和生物信息学
- 神经科学和神经学是神经科学和神经学.
- 基因组学和多基因组学
背景情况:
- 深度学习在科学上表现有前途,但与复杂的,高维的多维数据扎.
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,具有有限的向疗法.
- 血清代谢学,特别是脂管学,为阿尔茨海默病的预测提供了一个潜在的途径.
研究的目的:
- 引入循环滑动窗关联测试 (c-SWAT) 以提高AD分类.
- 为了提高使用血清脂管学数据的预测准确度.
- 为了识别与阿尔茨海默病相关的新型脂质生物标志物.
主要方法:
- 该c-SWAT方法包括特征相关性分析,特征选择和分类.
- 我们使用了阿尔茨海默病神经成像计划 (ADNI) 997名参与者的数据.
- 使用了权重基因共同表达网络分析 (WGCNA),卷积神经网络 (CNN) 和随机森林.
主要成果:
- c-SWAT实现了高达80.8%的分类准确度和AD预测的AUC为0.808.
- 与基线方法 (p < 1.04 × 10−4) 相比,这意味着准确度增加了9.4%,AUC增加了0.169.
- 确定了关键的AD相关脂质,包括Cer{d16:1/22:0) 和PI{37:6).
结论:
- c-SWAT有效地提高了对阿尔茨海默病预测的分类准确性.
- 该方法成功地识别了AD的潜在脂质生物标志物.
- 这些发现为AD病原体提供了新的见解,并为未来的研究提供了途径.
相关概念视频
Alzheimer's Disease: Overview
506
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
506
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


